Journal
ANTICANCER RESEARCH
Volume 40, Issue 1, Pages 153-160Publisher
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.13936
Keywords
Pancreatic ductal adenocarcinoma; cancer metabolism; combination therapy; polytherapy; anti-diabetic medication
Categories
Funding
- B. BRAUN-STIFTUNG [BBST-D-15-00003]
Ask authors/readers for more resources
Background/Aim: In this study, we evaluated the effect of galloflavin, an inhibitor of lactate dehydrogenase, in combination with metformin, an anti-diabetic drug and inhibitor of oxidative phosphorylation, on pancreatic ductal adenocarcinoma cells. Materials and Methods: We explored the effect of galloflavin and metformin on proliferation and cell death of murine 6606PDA and human MIA PaCa- 2 cells. Results: We observed that monotherapies of galloflavin and metformin both inhibit proliferation and induce cancer cell death. Moreover, the combination of both agents increased these effects on pancreatic ductal adenocarcinoma cells. The inhibition of proliferation by this combination therapy can be detected under hypoxic and normoxic conditions, leading to the assumption that this therapy might impair insufficiently supplied solid tumors as well as small clusters of cancer cells, e.g. after metastatic dissemination. Conclusion: Galloflavin, especially in combination with metformin, has a strong anti-cancerous effect on pancreatic ductal adenocarcinoma cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available